title: Peginterferon alfa related psoriasis in a patient with acute hepatitis C and review of the literature.
abstract: The Interferon (IFN) which is the standard treatment for Hepatitis C, may cause a lot of side effects including dermatological anomalies. This paper presents a psoriasis case which occurred in relation with the treatment of acute hepatitis C (AHC) with peginterferon alfa (peg-IFN-α). A 60-year-old male patient came to the hospital with symptoms of high liver enzymes. The patient with history of a recent operation showed anti-HCV(+), HCVRNA 3.5 million IU/mL and HCV genotype 1b in the tests. Without any other etiological factors found in the patient, we started a treatment of peg-IFNα-2b with the diagnosis of AHC. After 3 weeks, psoriatic plaques were observed in various parts of the body. Antiviral treatment of the patient was concluded within 6 months. His psoriasis treatment initially commenced with local agents followed by phototherapy. Permanent viral response was seen in the patient and his lesions recovered rapidly after the antipsoriatic and antiviral treatment. Psoriasis and other autoimmune diseases should be considered even though they are encountered rarely,and the patients should be informed of the possible risks before planning treatment with peg-IFN-α.
authors.affiliation: Faculty of Medicine, Department of Internal Medicine, Division of Gastroenterology, Gaziantep University, 27100, Sahinbey, Gaziantep, Turkey.
authors.forename: Muhammed Sait
authors.initials: MS
authors.lastname: Dag
authors.forename: Zeynel Abidin
authors.initials: ZA
authors.lastname: Oztürk
authors.forename: Nimet
authors.initials: N
authors.lastname: Yılmaz
authors.forename: Hakan
authors.initials: H
authors.lastname: Cam
authors.forename: Abdurrahman
authors.initials: A
authors.lastname: Kadayıfçı
mesh_terms: D003937:Diagnosis, Differential; D003875:Drug Eruptions / Q000175:diagnosis* / Q000209:etiology* / Q000517:prevention & control; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use*; D011565:Psoriasis / Q000139:chemically induced* / Q000175:diagnosis* / Q000517:prevention & control; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a
references.citation: Eur J Gastroenterol Hepatol. 2007 Sep;19(9):811-5
references.pmid: 17700270
references.citation: Eur J Dermatol. 2005 Mar-Apr;15(2):107-9
references.pmid: 15757824
references.citation: J Gastrointestin Liver Dis. 2006 Sep;15(3):249-56
references.pmid: 17013450
references.citation: Int J Clin Pract. 2010 Jan;64(1):101-3
references.pmid: 20089020
references.citation: Isr Med Assoc J. 2009 Dec;11(12):760-1
references.pmid: 20166347
references.citation: Can J Gastroenterol. 2009 Oct;23(10):677-83
references.pmid: 19826642
references.citation: Singapore Med J. 2011 Feb;52(2):e20-2
references.pmid: 21373724
references.citation: Gastroenterology. 2006 Jan;130(1):231-64; quiz 214-7
references.pmid: 16401486
references.citation: Australas J Dermatol. 2012 Nov;53(4):e69-72
references.pmid: 23157789
references.citation: Curr Gastroenterol Rep. 2001 Feb;3(1):30-7
references.pmid: 11177692
references.citation: Br J Dermatol. 1991 Nov;125(5):463-5
references.pmid: 1751354
references.citation: Clin Exp Dermatol. 2000 Jun;25(4):351-2
references.pmid: 10971502
references.citation: Scand J Infect Dis. 2013 Apr;45(4):320-3
references.pmid: 23113733
references.citation: Altern Med Rev. 2007 Dec;12(4):319-30
references.pmid: 18069901
references.citation: Ann Rheum Dis. 2011 Jul;70(7):1343-4
references.pmid: 21131645